

FGF19

Recombinant Human Fibroblast Growth Factor 19

| | | | |
|---------------------------------|--|------------------|-------------------------|
| Catalog No. | CRF153A CRF153B CRF153C | Quantity: | 5 µg 25 µg 1.0 mg |
| Alternate Names: | human FGF-19, h-FGF-19, rh-FGF-19, recombinant human FGF-19, recombinant FGF-9, FGF, FGF-19, FGF 19, FGF19 | | |
| Description: | Fibroblast growth factor-19 (FGF19) belongs to the large FGF family which has at least 23 members. All FGF family members are heparin binding growth factors with a core 120 amino acid (a.a.) FGF domain that allows for a common tertiary structure. FGFs are expressed during embryonic development and in restricted adult tissues. Four distinct but related classes of FGF receptors, FGF R1, 2, 3, and 4, exist. Unlike most FGFs which bind to and activate more than one FGF receptor, FGF19 is a specific ligand for FGF R4. | | |
| Gene ID: | 9965 | | |
| Protein Accession No: | NM_005117 | | |
| Source: | <i>E. coli</i> | | |
| Molecular Weight: | 21.8 kDa | | |
| Formulation: | Lyophilized from a 0.2µm filtered concentrated solution in PBS, pH 7.4. | | |
| Purity: | ≥95% as determined by SDS-PAGE and HPLC analysis | | |
| Endotoxin Level: | Less than 1EU/µg of rHuFGF-19 as determined by LAL method. | | |
| Biological Activity: | Fully biologically active when compared to standard. The ED ₅₀ determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 150 ng/ml. | | |
| Specific Activity: | ≥ 6.7 x 10 ³ IU/mg. | | |
| Amino Acid Sequence: | MRPLAFSDAG PHVHYGWGDP IRLRHLYTSG PHGLSSCFLR IRADGVVDCA RGQSAHSLLE IKAVALRTVA IKGVHSVRYL CMGADGKMQG LLQYSEEDCA FEEIIRPDGY NVYRSEKHRL PVSLSSAKQR QLYKNRGFLP LSHFLPMLPM VPEEPEDLRG HLESDFSSP LETDSMDPFG LVTGLEAVRS PSFEK | | |
| Reconstitution: | Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions. | | |
| Storage & Stability: | This lyophilized preparation is stable at 2-4°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-4°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -80°C. Avoid repeated freeze/thaw cycles. | | |

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

